Buflomedil
 | |
| Names | |
|---|---|
| IUPAC name
4-(pyrrolidin-1-yl)-1-(2,4,6-trimethoxyphenyl)butan-1-one | |
| Identifiers | |
55837-25-7  | |
| ChEMBL | ChEMBL188921 |
| ChemSpider | 2373 |
| Jmol interactive 3D | Image |
| PubChem | 2467 |
| UNII | V7I71DQ432 |
| |
| |
| Properties | |
| C17H25NO4 | |
| Molar mass | 307.38 g/mol |
| Pharmacology | |
| ATC code | C04 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is  ?) | |
| Infobox references | |
Buflomedil is a vasoactive drug used to treat claudication or the symptoms of peripheral arterial disease. It is currently not approved by the Food and Drug Administration (FDA) for use in the United States. Currently available as trade name tablet Loftyl
Toxicity
This drug might be suspended from marketing in the European Union, because of concerns about severe neurological and cardiac toxicity.[1][2] In its press release dated 17 November 2011 EMA suggested that doctors "should stop using buflomedil and consider alternative treatment options".
Various adverse effects have been reported to the FDA.[3]
References
| ||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Monday, November 30, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.